Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC).
Panagiota Economopoulou(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Nikolaos Oikonomopoulos(National and Kapodistrian University of Athens), Μaria Anastasiou(National and Kapodistrian University of Athens), Μαρία Γκοτζαμανίδου(National and Kapodistrian University of Athens), George Kavourakis(National and Kapodistrian University of Athens), Nikolaos Spathas(Metropolitan Hospital), George Papaxoinis(St Savas Hospital), Ioannis Kotsantis(National and Kapodistrian University of Athens), Euthymios Kirodimos, Elena Vagia(Northwestern University), Niki Gavrielatou(National and Kapodistrian University of Athens)
Cited by 4
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
The Landscape of Targeted Therapies in TNBC
|Cancers|2020|448
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160